还没做过化疗，EGFR是野生型的病友一定要去做ALK的检测

jzjqian 发表于 2012-7-25 15:45

7 r  K* y6 Q' |$ E5 W$ \! R0 o" P                               
登录/注册后可看大图

4 n& ^; G9 @& C4 @: o请教，像我这样的，手术22个月了，还能去原手术医院拿到病理作EGFR检查么？

可以，但要有针对性，

请问，肺鳞癌，只做过一次化疗，骨髓抑制严重，后吃特罗凯4个月基本无效，可以参加实验组吗？

不可以了,要没做过任何治疗的,包括化疗和靶向药

Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
1 T" A7 z: |2 b5 Y' y' s
2 s. X( B! G: ]6 v5 W" @
, C  v' x0 ^6 q7 s% y( o* ySub-category:
2 g$ Q& i: Y; qMolecular Targets


7 ^) ?2 h& g7 S9 L, r2 D# T/ oCategory:
Tumor Biology
9 U: p( V$ C! n8 |2 q  M0 ^) w% h
, J! ?- P0 }, S, r$ a
; t* H2 b! M# v( fMeeting:
2011 ASCO Annual Meeting
: [4 y" ]8 T6 N$ O

Session Type and Session Title:
Poster Discussion Session, Tumor Biology


Abstract No:
10517


: I/ Z- \  ~/ S9 l: Z+ MCitation:
J Clin Oncol 29: 2011 (suppl; abstr 10517)


" |4 {" C& ~1 p1 H* WAuthor(s):
# f" i; K5 g0 q! |) QJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
/ b* G# m' x; w. o


) Q: ]% @  x+ E* A  n2 ]Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.

Abstract Disclosures
& u3 \# l& B& l7 Q2 f- T+ U
4 ?$ H/ d  }$ V* nAbstract:

0 i1 J2 B6 t* n7 Z: g" G1 j
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
. G* Y; d- W- ~1 V

1 C" A9 B& u- n

由吴一龙教授牵头的A80810029临床试验上周启动，初诊未治疗的晚期肺腺癌患者检测到ALK阳性，可参加一线crizotinib 对比力比泰+卡铂的临床研究，药物全部免费，即使分配到力比泰组，疾病进展之后可免费获得crizotinib.

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

boeun 发表于 2012-11-18 16:37

' o! I3 q% U6 s' [. C8 H2 L7 P                               
登录/注册后可看大图

+ Z( P/ \3 j+ }* a& Y5 Q* a没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

* n( p0 i. R$ _5 m# `' j3 A: s2 D化疗过的没机会了

平安！ 发表于 2012-7-20 11:20

                               
登录/注册后可看大图

易瑞沙、特罗凯有效的病人基本上可以断定ALK（-）。极其罕见EGFR、ALK同时突变的。
ALK一个指标医院要900多 ...

: n7 A4 O% Y: e- s' g& V. m9 T8 H' q1 ?! ?平安，真的没有希望吗？我弟弟虽然特罗凯有效，但是ＥＧＦＲ是野生型，不是突变啊。有没有必要去检测ＡＬＫ呢？

# J5 f& j$ A# Q/ [) D) ?# ~+ ]2 I现在病情进展，快没招儿了。

好像想加入挺困难的

小地方没条件做啊